Levothyroxine therapy shows minimal overall effect on lipid and cardiometabolic biomarkers in older adults with subclinical hypothyroidism (SCH).
Potential beneficial lipid and lipoprotein profile changes were observed in individuals with baseline TSH ≥10 mIU/L, warranting further investigation.
Evidence from randomized controlled trials and meta-analyses indicates levothyroxine’s lipid-lowering effects are more pronounced in younger or milder SCH populations.
Adjunctive lifestyle interventions like Baduanjin exercise may complement pharmacotherapy by improving lipids and reducing TSH in elderly SCH patients.
